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Performances of the Rapid Polymyxin Acinetobacter
and Pseudomonas Tests for Colistin Susceptibility Testing
Mathilde Lescat,1–4 Laurent Poirel,1,2,5 Aure´lie Jayol,1,2,5 and Patrice Nordmann1,2,5,6
Objectives: Owing to the emergence of colistin resistance in nonfermenting Gram negative bacteria, reliable
and rapid techniques for testing colistin susceptibility are needed. We evaluated the performances of the Rapid
Polymyxin Acinetobacter and Pseudomonas tests using a collection of Acinetobacter baumannii and Pseudo-
monas aeruginosa clinical isolates.
Methods: Colistin susceptibility of A. baumannii and P. aeruginosa isolates (colistin susceptible and colistin
resistant) was tested with the Rapid Polymyxin Acinetobacter and Pseudomonas tests and compared with the
broth microdilution method.
Results: The Rapid Polymyxin Acinetobacter and Pseudomonas tests were able to detect all colistin-resistant
and all colistin-susceptible A. baumannii and P. aeruginosa isolates within 4 hours.
Conclusion: The Rapid Polymyxin Acinetobacter and Pseudomonas tests are reliable techniques for detecting
colistin resistance. Overall, both techniques allow an accurate and a rapid screening (<4 hours) of colistin
resistance in A. baumannii and P. aeruginosa.
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Introduction
Acinetobacter baumannii and Pseudomonas aerugi-nosa belong to the ESKAPE group of pathogens (En-
terococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aer-
uginosa, and Enterobacter species) identiﬁed as the most
important bacterial species in clinical settings as a source of
multidrug resistance.1 Infections due to multidrug-resistant
(MDR) A. baumannii and P. aeruginosa species, especially
carbapenem-resistant isolates, are increasingly reported in
health care facilities, being responsible for nosocomial in-
fections that may lead to fatal outcomes due to limited
therapeutic options.2–4 The Center for Diseases Control of
Atlanta in the United States and then the World Health
Organization classiﬁed the carbapenem-resistant A. bau-
mannii and P. aeruginosa among the most serious pathogens
exhibiting multidrug resistance.5,6 Consequently, old anti-
biotics such as polymyxins (colistin) are increasingly used
as last resort treatment for treating MDR A. baumannii and
P. aeruginosa.4,7 This highlights the importance of giving
rapid results of polymyxin susceptibility to optimize the
antibiotic stewardship.
The current standard method of detection for colistin
susceptibility in Gram negatives is the manual determination
of minimum inhibitory concentration (MIC) by the broth
microdilution (BMD) method.8 However, this procedure is
technician dependent (partly due to the fact that colistin
must be weighted for each experiment), is time consuming,
and results are obtained in 24 hours.
Recently, Nordmann et al. developed the Rapid Poly-
myxin Nordmann-Poirel (NP) test that categorizes colistin-
susceptible from colistin-resistant enterobacterial isolates in
<2 hours.9 However, this test based on visualization of glucose
metabolization cannot be applied to nonfermenting Gram
negative bacteria, such as A. baumannii and P. aeruginosa.
Using the same principle as the Rapid Polymyxin NP test,
the Rapid Polymyxin Acinetobacter and Pseudomonas tests
have recently been developed by Elitech Microbiology
(www.elitechgroup.com/france) and are liquid-based tech-
niques that rely on the colorimetric detection of a rapid
metabolism related to bacterial growth, in the presence of a
deﬁned concentration of colistin. The acidiﬁcation of the
medium related to bacterial growth is visualized by the color
shift of the pH indicator (red to yellow or orange with the
red phenol in the Rapid Polymyxin Acinetobacter test and
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green to violet with bromocresol purple in the Rapid Poly-
myxin Pseudomonas test).
The objective of this study was to evaluate the perfor-
mance of those novel tests by comparison with the BMD
method using a collection of colistin-susceptible and colistin-
resistant A. baumannii and P. aeruginosa clinical isolates.
Materials and Methods
Bacterial strains
This study was carried out using 38 clinical isolates of
A.baumannii (n= 21) andP. aeruginosa (n= 17) identiﬁed at the
species level using the Microﬂex benchtop matrix assisted laser
desorption ionization-time of ﬂight (MALDI-TOF) mass spec-
trometer (Bru¨cker, Champs-sur-Marne, France). Nine out of the
21 A. baumannii isolates and 10 out of the 17 P. aeruginosa
isolates were susceptible to colistin. Twelve out of the 21 A.
baumannii and7out of the 17P.aeruginosa isolateswere colistin
resistant according toBMD testing. Isolateswere grownonLuria
Bertani (LB; Sigma, Saint Louis, MO) agar plates at 35C–2C
for 18hours. The colistin-susceptible strainP. aeruginosaATCC
27853 and the colistin-resistant Escherichia coli R2739 were
used as negative and positive controls, respectively, for the de-
termination ofMIC of colistin by the BMDmethod. None of the
colistin-resistant isolates carried a plasmid-encoded MCR-like
(MCR-1 to -4) colistin resistance determinant, as assessed by the
negative polymerase chain reaction results (data not shown).
Susceptibility testing
The BMD method was performed in triplicate and inter-
preted according to the EUCAST/CLSI joined guidelines8
as described.10
Table 1. Minimum Inhibitory Concentrations of Colistin (mg/L) Using the Broth Microdilution
Method and Results of the Rapid Polymyxin Acinetobacter and Pseudomonas Tests
Isolate Species Origin Phenotype
BMD
Rapid Polymyxin Acinetobacter/
Pseudomonas test
MIC colistin
(mg/L)
MIC colistin
(mg/L) Discrepanciesa
FR-242 Acinetobacter baumannii Switzerland S <0.12 £2 No
FR-243 A. baumannii Turkey S <0.12 £2 No
FR-244 A. baumannii Turkey S <0.12 £2 No
FR-245 A. baumannii Turkey S <0.12 £2 No
FR-246 A. baumannii Turkey S <0.12 £2 No
FR-247 A. baumannii Turkey S <0.12 £2 No
FR-248 A. baumannii Turkey S <0.12 £2 No
N4 A. baumannii Switzerland S 0.25 £2 No
N14 A. baumannii Switzerland S <0.12 £2 No
FR-250 A. baumannii Italy R 8 >4 No
FR-252 A. baumannii Italy R 64 >4 No
FR-253 A. baumannii Spain R 4 >4 No
FR-254 A. baumannii Spain R 16 >4 No
FR-255 A. baumannii Switzerland R 128 >4 No
FR-256 A. baumannii Turkey R 16 >4 No
FR-257 A. baumannii Turkey R 8 >4 No
FR-258 A. baumannii Turkey R 4 >4 No
FR-259 A. baumannii Turkey R 4 >4 No
FR-260 A. baumannii Turkey R >128 >4 No
FR-261 A. baumannii Turkey R 4 >4 No
FR-262 A. baumannii Turkey R >128 >4 No
ATCC 27853 Pseudomonas aeruginosa United States S <0.12 £2 No
FR-263 P. aeruginosa France S <0.12 £2 No
FR-264 P. aeruginosa France S <0.12 £2 No
FR-265 P. aeruginosa France S <0.12 £2 No
FR-266 P. aeruginosa France S <0.12 £2 No
FR-267 P. aeruginosa France S <0.12 £2 No
FR-268 P. aeruginosa France S <0.12 £2 No
FR-269 P. aeruginosa France S <0.12 £2 No
FR-270 P. aeruginosa France S 0.25 £2 No
FR-271 P. aeruginosa France S 0.25 £2 No
FR-274 P. aeruginosa France R 4 8 No
FR-275 P. aeruginosa France R 32 8 No
FR-276 P. aeruginosa France R 32 >8 No
FR-277 P. aeruginosa France R 16 8 No
FR-278 P. aeruginosa France R 128 >8 No
FR-279 P. aeruginosa France R 8 4 No
FR-281 P. aeruginosa France R 4 >8 No
The colistin-resistant isolates are shaded in gray.
BMD, broth microdilution; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
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Rapid Polymyxin Acinetobacter
and Pseudomonas tests
The Rapid Polymyxin Acinetobacter and Pseudomonas
tests from Elitech Microbiology (www.elitechgroup.com/
france) were performed according the manufacturer in-
structions. In brief, a standardized suspension of each isolate
is prepared using a medium speciﬁc to each species. A
speciﬁc volume of this suspension is then placed in the
different wells of the kit containing deﬁned amounts of
colistin to obtain ﬁnal concentrations of 0 (positive control),
2, and 4mg/L for both species, and in addition of 8mg/L for
P. aeruginosa. A supplementary well is used as a negative
control in which a suspension with only NaCl is prepared.
After 3–4 hours of incubation at 37C, a valid result is ob-
tained when a color shift is observed in the positive control
well, and no color shift in the negative control well. The
result is then read for each colistin containing well as an
MIC reading. For this evaluation, the results of suscepti-
bility/resistance to polymyxins for each isolate were ob-
served after 2 hours every 15 minutes until 4 hours.
Result analysis
The results obtained with the Rapid Polymyxin tests were
compared with those obtained with the reference BMD
method. In brief, discrepancies were determined to assess
their performance to detect colistin susceptibility. Very
major errors (VME) and major errors (ME) corresponding
to false-susceptible and false-resistant results, respectively,
were calculated as described elsewhere.11,12
Results
A total of 21 A. baumannii and 17 P. aeruginosa isolates
were included to evaluate the performances of the Rapid
Polymyxin Acinetobacter and Pseudomonas tests (Table 1).
All of the nine A. baumannii isolates deﬁned as colistin
susceptible according to the result of the BMD method
(MICs of colistin ranging from <0.125 to 0.25mg/L) were
identiﬁed as susceptible by the Rapid Polymyxin Acineto-
bacter test (Table 1). All of the 12 colistin-resistant A.
baumannii isolates (MICs of colistin ranging from 4 to
>128mg/L) were detected as colistin resistant by the Rapid
Polymyxin Acinetobacter test (Table 1). Out of the 10
colistin-susceptible P. aeruginosa isolates (MICs of colistin
ranging from <0.125 to 0.25mg/L), all were found suscep-
tible using the Rapid Polymyxin Pseudomonas test. All of
the seven colistin-resistant P. aeruginosa isolates (MICs of
colistin ranging from 4 to 128mg/L) were identiﬁed as co-
listin resistant by the Rapid Polymyxin Pseudomonas test
(Table 1). Interpretation of the results for all isolates was
obtained between 3 and 4 hours; no positive result was ob-
served before 3 hours.
Discussion
Out of the 19 colistin-susceptible A. baumannii and P.
aeruginosa isolates, the Rapid Polymyxin Acinetobacter test
identiﬁed correctly all susceptible isolates, hence no ME
(i.e., false resistance) was detected for both tests (speciﬁ-
cities of 100%). Out of the 19 colistin-resistant A. bau-
mannii and P. aeruginosa isolates, the Rapid Polymyxin
Acinetobacter and Pseudomonas tests were excellent with
no VME (i.e., false susceptibility; sensitivities of 100%).
This study showed that the Rapid Polymyxin Acineto-
bacter and Pseudomonas tests are reliable tools for detecting
resistance to colistin in A. baumannii and P. aeruginosa. In
comparison, BMD systems (Sensititre [ThermoFischer Di-
agnostics] and UMIC [Biocentric and MicroScan]) have
been evaluated and showed VME for the three systems and
ME for the MicroScan system.13 Moreover, these are the
ﬁrst tests that are available for determination of colistin
susceptibility in those species in <4 hours. However, other
evaluations with a higher number of isolates should be
performed to conﬁrm our results as well as at least a mul-
ticenter study and its possible interest directly from clinical
samples. Although MICs of colistin are only determined in
ranges (£ 2, comprised between 2 and 4mg/L, and >4mg/L
for A. baumannii and £ 2, comprised between 4 and 8mg/L,
and >8mg/L for P. aeruginosa) using those tests, they give
results of susceptibility/resistance categorization very rap-
idly, which is the most important feature with respect to the
treatment strategy and may contribute to optimize antibiotic
stewardship. Colistin is indeed often used to treat infections
caused by MDR A. baumannii and P. aeruginosa isolates,
mostly remaining susceptible to colistin.14 However, the
increasing trend of acquired colistin resistance observed in
those species, and particularly in A. baumannii,15 highlights
the interest to use such rapid tests able to efﬁciently detect
that resistance trait.
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